Register or Sign in to Save this opportunity, or Send an Inquiry.
New Receptor for Cdk5 and Tau-mediated AD Pathology_Seoul National Univ.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
New receptor for cdk5 and Tau-mediated AD pathology
Send an Inquiry

1. Background of Technology

1.1. Clinical implication of Tau modification in Alzheimer’s disease

- Clinical association of Tau hyper-phosphorylation with Alzheimer’s disease

: PHF(paired helical filament) with hyper-phosphorylated tau found in AD patients and Tauopathy

: Gsk and cdk5 kinase are responsible for Tau pathologic phosphorylation

- Clinical correlation of Tau aggregation with Alzheimer’s disease

           : Tau oligomer and aggregates found in AD patients and Tauopathy


1.2. Newly being developed but not successful yet

- Active initiation of Tau modification/aggregation pathology research

          : Compared to amyloid, less effort has been done. But active researches increase (2008, 2009, ICAD)

- Recent initiation with High through-put screening for Tau aggregation modulator

          : Development for cdk5 Inhibitors and screening of Tau aggregation blocker (2008, 2009 ICAD)


1.3. Limited screening assays and a few available targets for drug development

- A few targets, including GSK3b and cdk5/p25

          : Most laboratories or Biotech Inc. are working on a few targets known in public domain for tauopathy, such as GSK3b and cdk5. There are not many targets for drug development.  

-Competitive new targets needed

             : More targets are required, including upstream of GSK or cdk5 for Tau modification and aggregation etc.


2. Description on Technology Applied

2.1. Unique establishment of modified-Tau cell-based assay for high contents screening

- We established Tau aggregation cell-based assay and prepared cDNA library for screening

: Most laboratories have used in vitro aggregation assays using purified Tau for compound screening because there is little available cell-based assay system. We established modified Tau-based cell assay for tau aggregation. In contrast to other genome-wide screening, we collected human cDNA in a mammalian expression vector (>17,000) for gain-of-screening (Fig. 1).

-Successful high-content screening for gain-of-function using cDNA

             : From high-content screening using cDNA (>4,000 cDNA), we successfully isolated new genes and pathways which regulate Tau aggregation and hyper-phosphorylation.

2.2. R receptor: Isolation of new pathway (genes) for Tau phosphorylation/aggregation 

- In vitro characterization: Role of R receptor in Tau hyper-phosphorylation/aggregation

          : Expression or knockdown of R receptor modulates Tau phosphorylation/aggregation in neuronal cells. In addition, R receptor affects neuronal cell’s viability.

-R receptor as an upstream of cdk5 for Tau hyper-phosphorylation/aggregation

: R receptor seems to work at an upstream of cdk5 in cell level.

- in vivo characterization for neurotoxicity, providing proof of concept

             : In fly rough eye model, R receptor increases Tau-induced neuronal degeneration, while dominant negative mutant rescues the toxic effects induced by Tau.

             (* In R receptor knockout mice, R receptor seems to be viable but looks better smart).

Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833